Evidence map›Paper›PMID 27376958›Full record

ArticleScientific reports2016

MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2.

Biao Deng, Bin Wang, Jiaqing Fang, Xuchao Zhu, Zhongwei Cao, Qi Lin, Lisheng Zhou, Xing Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.Medical oncology (Northwood, London, England) · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Impact of miRNAs expression modulation on the methylation status of breast cancer stem cell-related genes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Biao DengDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
Bin WangDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
Jiaqing FangDepartment of Gastroenterology, Tianyou Hospital, TongJi University, 500 Zhennan Road, Shanghai, 200331, China.
Xuchao ZhuDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, TongJi University, 301 Yanchang Road, Shanghai, 200072, China.
Zhongwei CaoDepartment of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
Qi LinDepartment of General Surgery, Zhongshan Hospital, Fudan University, 180 Xietu Road, Shanghai, 200032, China.
Lisheng ZhouDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
Xing SunDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
Shanghai Jiao Tong University · CNShanghai First People's Hospital · CNShanghai Tenth People's Hospital · CNTongji University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While it is known that miR-203 is frequently downregulated in many types of human cancer, little is known regarding its expression and functional role in colorectal cancer (CRC). In this study, we aimed to investigate the expression and the potential mechanisms of miR-203 in colorectal cancer. MiR-203 was significantly downregulated in CRC tissues compared with matched normal adjacent tissues. Our clinical data show that decreased miR-203 was associated with an advanced clinical tumor-node-metastasis stage, lymph node metastasis, and poor survival in CRC patients. Furthermore, externally induced expression of miR-203 significantly inhibited CRC cell proliferation and invasion in vitro and in vivo. Mechanistically, we identified EIF5A2 as a direct and functional target of miR-203. The levels of miR-203 were inversely correlated with levels of the EIF5A2 in the CRC tissues. Restoration of EIF5A2 in the miR-203-overexpressing CRC cells reversed the suppressive effects of miR-203. Our results demonstrate that miR-203 serves as a tumor suppressor gene and may be useful as a new potential therapeutic target in CRC.

Indexed as

AnimalsCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsDown-RegulationEukaryotic Translation Initiation Factor 5AGene Expression Regulation, NeoplasticHEK293 CellsHT29 CellsHumansLymphatic MetastasisMiceMice, Inbred BALB CMice, NudeMicroRNAsEukaryotic Translation Initiation Factor 5AMicroRNAsMIRN203 microRNA, humanPeptide Initiation FactorsRNA-Binding Proteins

Identifiers

PMID27376958
PMCPMC4931903
OpenAlexW2472320849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.